Legend Biotech Financials
LEGN Stock  USD 55.90 1.01 1.77% 
Current Value  Last Year  Change From Last Year  10 Year Trend  

Current Ratio  7.27  6.9209 


The financial analysis of Legend Biotech is a critical element in measuring its lifeblood. Investors should not minimize Legend Biotech's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income 

Legend  Select Account or Indicator 
Understanding current and past Legend Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Legend Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in Legend Biotech's assets may result in an increase in income on the income statement.
Legend Biotech Stock Summary
Legend Biotech competes with Biovie, In8bio, Tff Pharmaceuticals, Inhibrx, and Enliven Therapeutics. Legend Biotech Corporation, a clinicalstage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. Legend Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1071 people.Specialization  Health Care, Pharmaceuticals, Biotechnology & Life Sciences 
Instrument  USA Stock View All 
Exchange  NASDAQ Exchange 
ISIN  US52490G1022 
CUSIP  52490G102 
Location  New Jersey; U.S.A 
Business Address  2101 Cottontail Lane, 
Sector  Biotechnology 
Industry  Health Care 
Benchmark  Dow Jones Industrial 
Website  www.legendbiotech.com 
Phone  732 317 5050 
Currency  USD  US Dollar 
Legend Biotech Key Financial Ratios
Legend Biotech's financial ratios allow both analysts and investors to convert raw data from Legend Biotech's financial statements into concise, actionable information that can be used to evaluate the performance of Legend Biotech over time and compare it to other companies across industries.Return On Equity  0.51  
Profit Margin  (1.36) %  
Operating Margin  (1.25) %  
Price To Sales  29.28 X  
Revenue  285.14 M 
Legend Biotech Key Balance Sheet Accounts
2019  2020  2021  2022  2023  2024 (projected)  
Total Assets  287.7M  721.0M  1.1B  1.3B  1.8B  938.8M  
Other Current Liab  70.9M  99.2M  211.4M  260.9M  140.1M  147.9M  
Other Liab  277.8M  277.7M  244.8M  7.9M  7.1M  6.7M  
Net Tangible Assets  (123.4M)  277.4M  466.5M  740.9M  852.0M  894.6M  
Retained Earnings  (127.3M)  (430.8M)  (817.0M)  (966.5M)  (1.5B)  (1.4B)  
Accounts Payable  9.6M  5.2M  7.0M  32.9M  20.2M  13.6M  
Cash  83.4M  455.7M  688.9M  786.0M  1.3B  1.3B  
Other Assets  665K  4.2M  7.3M  67.7M  1.0  0.95  
Net Receivables  35.8M  85.0M  63.2M  90K  157.1M  164.9M  
Inventory  1.2M  1.8M  1.7M  10.4M  19.4M  20.4M  
Total Liab  410.6M  440.8M  647.2M  586.7M  589.9M  522.0M  
Total Current Assets  207.1M  592.9M  948.8M  1.1B  1.5B  770.5M  
Intangible Assets  5.1M  7.7M  4.7M  3.4M  155.3M  163.0M  
Net Debt  (77.3M)  (452.3M)  (566.0M)  (501.5M)  (949.4M)  (901.9M)  
Other Current Assets  11.3M  580.7M  1.4M  1.1B  12.2M  11.6M  
Net Invested Capital  (122.9M)  280.3M  591.7M  1.0B  1.5B  1.6B  
Net Working Capital  79.3M  431.7M  668.5M  801.3M  1.3B  1.3B  
Short Term Debt  1.0M  1.5M  911K  3.6M  3.2M  1.9M 
Legend Biotech Key Income Statement Accounts
2019  2020  2021  2022  2023  2024 (projected)  
Tax Provision  2.6M  (4.1M)  1K  625K  283K  268.9K  
Interest Expense  223K  4.2M  900K  10.8M  21.8M  22.9M  
Total Revenue  57.3M  75.7M  89.8M  117.0M  285.1M  299.4M  
Operating Income  (130.9M)  (313.3M)  (393.0M)  (455.8M)  (442.2M)  (420.1M)  
Ebit  (130.9M)  (313.3M)  (393.0M)  (455.8M)  (442.2M)  (420.1M)  
Income Before Tax  (130.4M)  (307.6M)  (386.2M)  (445.7M)  (520.1M)  (494.1M)  
Net Income  (133.0M)  (303.5M)  (386.2M)  (446.3M)  (518.3M)  (492.3M)  
Income Tax Expense  2.6M  (4.1M)  1K  625K  (1.9M)  (1.8M)  
Net Interest Income  4.4M  (4.2M)  (900K)  (10.8M)  21.2M  22.3M  
Interest Income  4.6M  2.9M  971K  8.2M  42.1M  44.2M  
Gross Profit  57.3M  (156.5M)  (223.6M)  51.6M  120.5M  126.5M  
Research Development  161.9M  232.2M  313.3M  335.6M  382.2M  272.4M  
Ebitda  (125.6M)  (303.4M)  (379.1M)  (437.4M)  (421.8M)  (442.9M) 
Legend Biotech Key Cash Accounts
2019  2020  2021  2022  2023  2024 (projected)  
Change To Inventory  (22K)  (643K)  51K  (8.6M)  (12.7M)  (12.1M)  
Investments  (58.7M)  25.6M  (195.0M)  (78.3M)  92.8M  97.4M  
Change In Cash  (126.8M)  372.3M  233.2M  97.1M  490.8M  515.3M  
Net Borrowings  14.7M  (2.6M)  (1.4M)  (2.6M)  (2.3M)  (2.2M)  
Depreciation  5.3M  9.9M  13.9M  18.4M  20.5M  11.0M  
Capital Expenditures  39.2M  49.8M  47.1M  22.3M  121.5M  127.6M  
Net Income  (130.4M)  (307.6M)  (386.2M)  (445.7M)  (518.3M)  (492.3M)  
End Period Cash Flow  83.4M  455.7M  688.9M  786.0M  1.3B  1.3B  
Change To Netincome  (7.8M)  92.0M  187.7M  34.2M  39.3M  55.1M  
Free Cash Flow  (122.2M)  (272.8M)  (245.6M)  (222.3M)  (506.0M)  (480.7M)  
Other Non Cash Items  (4.4M)  84.6M  187.7M  6.6M  349.9M  367.4M 
Legend Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Legend Biotech's current stock value. Our valuation model uses many indicators to compare Legend Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Legend Biotech competition to find correlations between indicators driving Legend Biotech's intrinsic value. More Info.Legend Biotech Corp is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . At this time, Legend Biotech's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the pricetoearnings (P/E), pricetobook (P/B), pricetosales (P/S), pricetocash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Legend Biotech's earnings, one of the primary drivers of an investment's value.Legend Biotech Corp Systematic Risk
Legend Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a welldiversified portfolio. Legend Biotech volatility which cannot be eliminated through diversification, requires returns over the riskfree rate. Over the long run, a welldiversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a tradeoff between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Legend Biotech Corp correlated with the market. If Beta is less than 0 Legend Biotech generally moves in the opposite direction as compared to the market. If Legend Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Legend Biotech Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Legend Biotech is generally in the same direction as the market. If Beta > 1 Legend Biotech moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Legend Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Legend Biotech's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Legend Biotech growth as a starting point in their analysis.
Price Earnings To Growth Ratio 

Legend Biotech August 9, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Legend Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Legend Biotech Corp. We use our internallydeveloped statistical techniques to arrive at the intrinsic value of Legend Biotech Corp based on widely used predictive technical indicators. In general, we focus on analyzing Legend Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Legend Biotech's daily price indicators and compare them against related drivers.
Downside Deviation  3.02  
Information Ratio  0.1135  
Maximum Drawdown  16.38  
Value At Risk  (5.01)  
Potential Upside  5.56 
Additional Information and Resources on Investing in Legend Stock
When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a wellinformed decision on Legend Biotech Corp Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.58)  Revenue Per Share 1.902  Quarterly Revenue Growth 1.587  Return On Assets (0.18)  Return On Equity (0.51) 
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.